66P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

ConclusionThis updated analysis continues to show the clinical benefit and manageable safety profile of nintedanib plus docetaxel in pts with advanced adenocarcinoma NSCLC following treatment with chemotherapy and ICIs.Clinical trial identificationNCT02392455.Legal entity responsible for the studyBoehringer Ingelheim Pharma GmbH& Co. KG.FundingBoehringer Ingelheim Pharma GmbH& Co. KG.DisclosureC. Grohe: Advisory / Consultancy: Boehringer Ingelheim. H. Mueller-Huesmann: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): BMS; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self): AstraZeneca. J. Atz: Full / Part-time employment: Boehringer Ingelheim. R. Kaiser: Full / Part-time employment: Boehringer Ingelheim.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research